Spreadsheet: 96448d1295859018-settings-changed-for-default-cell-format-want-to-change-it-back-to-general-excelforum_yongsonneedshelp
Sheet: investors basis

1
0000_BIOMED_SHOW_FinancingInvestors
FinancingID | InvestorID | InvestorRole | InvestorName | LegalForm | LegalType | [NAME] | Country | Continent | BiotechMainSegment | TherapeuticStatus | ID + LeadInvestor Continent | Lead Investor Segment | Lead Investor Continent
1 | 2631 | Buyer | Shire | PLC | Headquarters | BIO-DR | UK | Europe | BIO-TH | Marketed
2 | 20023 | Buyer | Allos Therapeutics | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Phase II
5 | 20016 | Buyer | Affymetrix | Inc. | Headquarters | DIA-LAB | US | Americas | BIO-STT
6 | 22034 | Buyer | Anaptys Biosciences | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Preclinical
8 | 873 | Buyer | Cancer Research Technology | Ltd. | Not for profit | [NAME] | UK | Europe
11 | 3004 | Buyer | [NAME] | S.p.A. | Headquarters | BIO-DR | IT | Europe | BIO-TH | Phase III
12 | 1261 | Buyer | Medical Research Council Technology |  | Headquarters | [NAME] | UK | Europe
14 | 22637 | Buyer | Virium Pharmaceuticals (acquired by MacroChem in 2008) |  | Headquarters | BIO-DR | US | Americas | BIO-TH | Phase II
15 | 733 | Buyer | Santen Pharmaceutical |  |  | BIO-DR | J | Asia/Pacific | BIO-TH
16 | 959 | Buyer | GlaxoWellcome/ SmithKline Beecham |  | Headquarters | PH-DR | UK | Europe
17 | 973 | Buyer | Pfizer | Inc. | Headquarters | PH-DR | US | Americas |  | Registration
18 | 19954 | Buyer | Procter & Gamble Pharmaceuticals |  | Subsidiary | PH-DR | US | Americas |  | Registration
19 | 972 | Buyer | [NAME] | Corp. | Headquarters | PH-DR | UK | Europe
20 | 20056 | Buyer | [NAME] | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
21 | 20028 | Buyer | Amgen | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
22 | 970 | Buyer | [NAME] |  | Headquarters | PH-DR | US | Americas |  | Registration
23 | 972 | Buyer | [NAME] | Corp. | Headquarters | PH-DR | UK | Europe
24 | 749 | Buyer | Rhone-Poulenc Rorer |  |  | PH-DR | F | Europe
25 | 945 | Buyer | Bayer | AG | Headquarters | PH-DR | D | Europe |  | Marketed
26 | 22511 | Buyer | Allergan | Inc. | Headquarters | BIO-DR | US | Americas
27 | 956 | Buyer | Sanofi-Aventis | S.A. | Headquarters | PH-DR | F | Europe |  | Marketed
28 | 959 | Buyer | GlaxoWellcome/ SmithKline Beecham |  | Headquarters | PH-DR | UK | Europe
29 | 20316 | Buyer | Targeted Genetics | Corp. | Headquarters | BIO-DR | US | Americas | BIO-TH | Phase II
30 | 956 | Buyer | Sanofi-Aventis | S.A. | Headquarters | PH-DR | F | Europe |  | Marketed
31 | 945 | Buyer | Bayer | AG | Headquarters | PH-DR | D | Europe |  | Marketed
32 | 959 | Buyer | GlaxoWellcome/ SmithKline Beecham |  | Headquarters | PH-DR | UK | Europe
33 | 746 | Buyer | Hoechst | AG |  | PH-DR | D | Europe
34 | 915 | Buyer | Warner-Lambert |  |  | PH-DR | US | Americas |  | Approved
35 | 948 | Buyer | Teva Pharmaceutical Industries | Ltd. | Headquarters | PH-GEN | ISR | Europe |  | Marketed
36 | 20138 | Buyer | Genentech | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
38 | 970 | Buyer | [NAME] |  | Headquarters | PH-DR | US | Americas |  | Registration
39 | 970 | Buyer | [NAME] |  | Headquarters | PH-DR | US | Americas |  | Registration
40 | 970 | Buyer | [NAME] |  | Headquarters | PH-DR | US | Americas |  | Registration
43 | 889 | Buyer | Tanox |  | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
44 | 956 | Buyer | Sanofi-Aventis | S.A. | Headquarters | PH-DR | F | Europe |  | Marketed
45 | 7177 | Buyer | Merck | [NAME] | Headquarters | PH-DR | D | Europe
46 | 956 | Buyer | Sanofi-Aventis | S.A. | Headquarters | PH-DR | F | Europe |  | Marketed
47 | 3267 | Buyer | UCB Group | S.A. | Headquarters | PH-DR | B | Europe |  | Marketed
48 | 994 | Buyer | Chiron |  | Headquarters | BIO-DR | US | Americas | BIO-TH
49 | 971 | Buyer | Monsanto | Co. | Headquarters | AGC | US | Americas
50 | 7220 | Buyer | Fujisawa |  | Headquarters | BIO-DD | J | Asia/Pacific | BIO-TH
51 | 959 | Buyer | GlaxoWellcome/ SmithKline Beecham |  | Headquarters | PH-DR | UK | Europe
52 | 745 | Buyer | Aventis |  |  | PH-DR | F | Europe
53 | 20138 | Buyer | Genentech | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
54 | 10976 | Buyer | Hitachi Medical Corporation | Corp. | Subsidiary | MED-NC | J | Asia/Pacific
56 | 2676 | Buyer | Elan Corporation | PLC | Headquarters | BIO-DR | IRL | Europe | BIO-TH | Marketed
57 | 20038 | Buyer | Arena Pharmaceuticals | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Phase III
58 | 20307 | Buyer | SuperGen | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Phase III
59 | 20138 | Buyer | Genentech | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
60 | 7024 | Buyer | Boehringer [NAME] | GmbH & Co. KG | Subsidiary | PH-DR | D | Europe |  | Marketed
61 | 1053 | Buyer | [NAME] | Inc. | Headquarters | MED-DD | US | Americas | BIO-TH | Phase III
62 | 915 | Buyer | Warner-Lambert |  |  | PH-DR | US | Americas |  | Approved
63 | 957 | Buyer | Bristol-Myers Squibb | Co. | Headquarters | PH-DR | US | Americas |  | Approved
64 | 973 | Buyer | Pfizer | Inc. | Headquarters | PH-DR | US | Americas |  | Registration
65 | 22200 | Buyer | Tripos International | Inc. |  | BIO-DDSA | US | Americas | BIO-STT
66 | 20222 | Buyer | [NAME] | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Phase II
67 | 959 | Buyer | [NAME] | PLC | Headquarters | PH-DR | UK | Europe
68 | 22245 | Buyer | Immunex | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH
69 | 956 | Buyer | Sanofi-Aventis | S.A. | Headquarters | PH-DR | F | Europe |  | Marketed
70 | 19961 | Buyer | Taisho Pharmaceutical | Co. |  | PH-DR | J | Asia/Pacific
71 | 21946 | Buyer | Purdue Pharma | LP | Headquarters | PH-DR | US | Americas
72 | 2631 | Buyer | Shire | PLC | Headquarters | BIO-DR | UK | Europe | BIO-TH | Marketed
73 | 970 | Buyer | [NAME] |  | Headquarters | PH-DR | US | Americas |  | Registration
74 | 798 | Buyer | Abgenix | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH
75 | 20138 | Buyer | Genentech | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
76 | 20028 | Buyer | Amgen | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
77 | 19961 | Buyer | Taisho Pharmaceutical | Co. |  | PH-DR | J | Asia/Pacific
78 | 20078 | Buyer | Cephalon | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
79 | 20201 | Buyer | Medarex | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Registration
80 | 19954 | Buyer | Procter & Gamble Pharmaceuticals |  | Subsidiary | PH-DR | US | Americas |  | Registration
81 | 20056 | Buyer | [NAME] | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
82 | 995 | Buyer | Roche |  | Headquarters | PH-DR | CH | Europe |  | Marketed
83 | 798 | Buyer | Abgenix | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH
84 | 996 | Buyer | Novartis International | AG | Headquarters | PH-DR | CH | Europe |  | Marketed
85 | 995 | Buyer | Roche |  | Headquarters | PH-DR | CH | Europe |  | Marketed
86 | 2676 | Buyer | Elan Corporation | PLC | Headquarters | BIO-DR | IRL | Europe | BIO-TH | Marketed
87 | 970 | Buyer | [NAME] |  | Headquarters | PH-DR | US | Americas |  | Registration
88 | 912 | Buyer | Daiichi Sankyo Company | Ltd. | Headquarters | PH-DR | J | Asia/Pacific
89 | 7024 | Buyer | Boehringer [NAME] | GmbH & Co. KG | Subsidiary | PH-DR | D | Europe |  | Marketed
90 | 22317 | Buyer | Bradley Pharmaceuticals | Inc. |  | PH-DR | US | Americas | BIO-TH
91 | 3840 | Buyer | Biovitrum | Ab | Headquarters | BIO-DR | SW | Europe | BIO-TH | Marketed
92 | 20138 | Buyer | Genentech | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
94 | 973 | Buyer | Pfizer | Inc. | Headquarters | PH-DR | US | Americas |  | Registration
95 | 930 | Buyer | Sigma-Aldrich | Corp. | Headquarters | REA | US | Americas
96 | 505 | Buyer | Bayer Healthcare Wuppertal | AG | Branch | PH-DR | D | Europe
103 | 22295 | Buyer | Ardea Biosciences | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Phase II
104 | 6165 | Buyer | [NAME] (acquired by Nycomed) | AG | Subsidiary | PH-DR | D | Europe
105 | 945 | Buyer | Bayer | AG | Headquarters | PH-DR | D | Europe |  | Marketed
106 | 20239 | Buyer | Onyx Pharmaceuticals | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
107 | 7024 | Buyer | Boehringer [NAME] | GmbH & Co. KG | Subsidiary | PH-DR | D | Europe |  | Marketed
108 | 20201 | Buyer | Medarex | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Registration
109 | 8021 | Buyer | Peptech Ltd |  | Headquarters | BIO-DR | AU | Asia/Pacific | BIO-TH
110 | 10976 | Buyer | Hitachi Medical Corporation | Corp. | Subsidiary | MED-NC | J | Asia/Pacific
111 | 20201 | Buyer | Medarex | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Registration
112 | 20202 | Buyer | MedImmune | Inc. | Headquarters | BIO-DR | US | Americas | BIO-TH | Marketed
114 | 911 | Buyer | Eisai | Co. Ltd. | Headquarters | PH-DR | J | Asia/Pacific